RxDoctor Payments Data

Michael Hardee, MD

Cardiovascular Disease · Austell, GANPI 1215922299

Payments from drug & device makers

$5,773in general payments, 2019–2025

Across 293 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Johnson & Johnson$499
  • Merck$476
  • Amgen$432
  • Boehringer Ingelheim$319
  • Boston Scientific$305
  • plus $3K from 22 others

What the payments were for

  • Food & beverage$5,773100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,773 in reported general payments places this provider in the 70th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$164,139
Medicare patients
1,343
Services billed
2,758

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban479$511,741
EntrestoSacubitril/Valsartan132$129,808
XareltoRivaroxaban84$91,409
JardianceEmpagliflozin60$62,705
FarxigaDapagliflozin Propanediol15$16,293
Repatha SureclickEvolocumab23$14,992
Ranolazine ErRanolazine67$11,361
BrilintaTicagrelor15$8,252
Repatha SyringeEvolocumab11$7,272
Metoprolol Succinate586$5,779
Carvedilol644$4,277
Valsartan226$4,168
Hydralazine Hcl359$4,131
Rosuvastatin Calcium340$3,431
Isosorbide Mononitrate ErIsosorbide Mononitrate249$3,415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$275$511,741479 claims
NovartisEntresto$1,001$129,808132 claims
Johnson & JohnsonXarelto$499$91,40984 claims
Boehringer IngelheimJardiance$319$62,70560 claims
AstraZenecaFarxiga, Brilinta$271$24,54630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Austell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →